Management of Vortioxetine‑Induced Nausea

Pharmacologic Antiemetic Options

5‑HT₃ receptor antagonists (e.g., ondansetron 4–8 mg twice or three times daily) are recommended to treat persistent nausea in patients receiving vortioxetine. [National Comprehensive Cancer Network (NCCN) guidelines] [1]
Granisetron (1 mg twice daily or a transdermal patch delivering 34.3 mg weekly) is an alternative 5‑HT₃ antagonist for the same indication. [NCCN] [2]
Dopamine‑type antagonists such as prochlorperazine 5–10 mg four times daily can be used when 5‑HT₃ antagonists alone are insufficient. [NCCN] [3]

If nausea persists with a single agent, adding a second antiemetic with a different mechanism (e.g., combining a 5‑HT₃ antagonist with a dopamine antagonist) improves symptom control without replacing the first drug. [NCCN] [1]
Serotonergic antiemetics are associated with a lower incidence of central nervous system side‑effects compared with dopaminergic agents. [NCCN] [3]

Before initiating antiemetic therapy, clinicians should rule out other contributors to nausea such as constipation, central nervous system pathology, hypercalcemia, and concomitant medications. [NCCN] [3]

The oral solution of vortioxetine is bioequivalent to tablet formulations (AUC₀‑₇₂h ratio = 1.06; 90 % CI = 1.03–1.10), permitting individualized dosing and gradual titration to mitigate nausea. [Clinical Gastroenterology and Hepatology] [1]
Utilizing the oral solution enables personalized dose adjustments and a slow titration schedule, which have been shown to reduce the incidence of nausea. [Clinical Gastroenterology and Hepatology] [1]

If nausea remains after one week of optimized antiemetic therapy, a second agent from a different pharmacologic class (e.g., prochlorperazine) should be added. [NCCN] [3]
Antiemetics should be administered on a scheduled basis (rather than PRN) for at least one week to achieve adequate control. [NCCN] [4]